SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : CLTR COULTER PHARMACEUTICAL
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: biowa who wrote (458)12/10/1999 10:19:00 PM
From: Bob L  Read Replies (1) of 666
 
<I still think the issue of excluding patients from the Zev clinical trials based on the In-dosimetry could be sticky. >

In the article linked in reply #413, they say: "All patients were eligible for IDEC-Y2B8 treatment on day 7 based on MIRDOSE3 software (Oak Ridge Associated Universities, Oak Ridge, TN) dosimetry estimates from the IDEC-In2B8 scans and IDEC-In2B8 blood activity. The upper limit of acceptable radiation dose was defined as 20 Gy for normal organs and 3 Gy for bone marrow. One patient was not treated based on site-specific (non-MIRDOSE), image-based, bone marrow dosimetry, although the estimated marrow radiation dose was acceptable on blood-derived and sacral image—derived MIRDOSE3 dosimetry performed by the central dosimetrist (Oak Ridge Institute for Science and Education)."

I can't quite figure out what they are saying about why they didn't treat one patient. Can someone dumb it down for me?
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News